Venlafaxine Extended-Release Dosing
Start venlafaxine ER at 37.5-75 mg once daily, increase by 75 mg weekly as tolerated, targeting an efficacious dose of 150-225 mg/day for most indications, with a maximum of 225 mg/day for neuropathic pain and up to 375 mg/day for severe depression. 1, 2
Initial Dosing Strategy
For depression and anxiety disorders:
- Start at 37.5 mg once or twice daily (or 75 mg once daily for immediate-release formulation) 1, 2
- The extended-release formulation permits once-daily dosing due to its long elimination half-life 3
- Take with food to improve tolerability 2
Titration schedule:
- Increase by 75 mg increments weekly 1
- Allow at least 4 days between dose increases 2
- Titration to efficacious doses typically requires 2-4 weeks 1
Target Therapeutic Doses
For neuropathic pain (diabetic peripheral neuropathy, painful polyneuropathies):
- Target dose: 150-225 mg/day 1, 4
- Maximum dose: 225 mg/day 1
- Duration of adequate trial: 4-6 weeks at target dose 1
For major depressive disorder:
- Outpatients: 75-225 mg/day is effective for most patients 2
- Severely depressed inpatients: Mean effective dose ~350 mg/day 2
- Maximum dose: 375 mg/day in divided doses 2
- Recent evidence suggests 200 mg/day may offer optimal efficacy-tolerability balance 5
- Therapeutic blood level range (active moiety): 140-600 ng/mL 6
For anxiety disorders (generalized anxiety, social anxiety, panic disorder):
- Effective dose range: 75-225 mg/day 7, 8
- Both 75 mg/day fixed dose and 150-225 mg/day flexible dosing show comparable efficacy 8
Special Population Adjustments
Hepatic impairment:
- Reduce total daily dose by 50% in mild-to-moderate hepatic impairment 2
- May require >50% reduction in cirrhosis due to individual variability 2
Renal impairment:
- Mild-to-moderate (GFR 10-70 mL/min): Reduce total daily dose by 25% 2
- Hemodialysis: Reduce total daily dose by 50% 2
Elderly patients:
- No routine dose adjustment required based on age alone 2
- Use extra caution when titrating; consider slower increases 1
Critical Safety Considerations
Cardiovascular monitoring:
- Monitor blood pressure regularly—venlafaxine can cause sustained hypertension and blood pressure increases 1, 3
- Use with caution in cardiac disease; cardiac conduction abnormalities reported 1
- Consider baseline ECG in patients >40 years or with cardiac history 1
Discontinuation:
- Always taper gradually—withdrawal syndrome is well-documented 1, 3, 2
- Reduce dose slowly rather than stopping abruptly 2
- If intolerable symptoms occur during taper, resume previous dose and decrease more gradually 2
MAOI interactions:
- Allow 14 days after stopping MAOI before starting venlafaxine 2
- Allow 7 days after stopping venlafaxine before starting MAOI 2
Dose-Response Relationship
The evidence demonstrates a clear dose-dependent mechanism: venlafaxine primarily inhibits serotonin reuptake at lower doses (75-150 mg/day), with norepinephrine reuptake inhibition becoming clinically significant at higher doses (≥150 mg/day) 3, 9, 6. This dual mechanism explains why non-responders at lower doses may benefit from titration to 150-225 mg/day 10, 6.
Higher doses (300-375 mg/day):
- May produce faster response on some measures 10
- Associated with increased adverse effects (constipation, sweating, hypertension, agitation, urinary frequency) 10
- Reserve for treatment-resistant cases or severe depression 2
- Slower titration to higher doses improves tolerability 10
Common Pitfalls to Avoid
- Inadequate titration time: Allow full 2-4 weeks to reach therapeutic doses; premature discontinuation is common 1
- Underdosing: Many patients receive subtherapeutic doses in clinical practice compared to trial doses 4
- Abrupt discontinuation: Always taper to prevent withdrawal syndrome 1
- Ignoring blood pressure: Regular monitoring is essential, especially at higher doses 1, 3